Table 2.
Subject immunosuppressive treatment characteristics.
| Control (n = 10) | Active (n = 13) | Quiescent (n = 37) | |
|---|---|---|---|
| On oral immunosuppressive treatment at baseline, no. (%) | – | 6 (46) | 0 (0) |
| Previous oral immunosuppression received, no. (%) | 10 (77) | 37 (100) | |
| Prednisolone only | 4 (40) | 22 (59) | |
| Additional second-line immunosuppression | 6 (60) | 15 (41) | |
| Mycophenolate mofetil | – | 3 (23) | 5 (14) |
| Ciclosporin | – | 0 (0) | 7 (20) |
| Azathioprine | – | 1 (8) | 2 (5) |
| Methotrexate | – | 0 (0) | 1 (3) |
| Biologicals | – | 0 (0) | 1 (3) |
| Median duration of previous oral immunosuppression, months (IQR) | – | 6 (4–12) | 24 (7–72) |
Median values are in bold font.